KCNE4 (Potassium Voltage-Gated Channel Subfamily E Regulatory Subunit 4)

📖 Wiki Page

gene1570 wordssynced 2026-04-02

KCNE4 (Potassium Voltage-Gated Channel Subfamily E Regulatory Subunit 4)

Overview

...

KCNE4 (Potassium Voltage-Gated Channel Subfamily E Regulatory Subunit 4)

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">KCNE4 (Potassium Voltage-Gated Channel Subfamily E Regulatory Subunit 4)</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>KCNE4</td>
</tr>
<tr>
<td class="label">Alternative Names</td>
<td>MiRP4, EPLG4</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>2q36.1</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>23704</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>607334</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9P110</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>180 amino acids</td>
</tr>
<tr>
<td class="label">Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Hippocampus (CA1, CA3)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Cortex (layers II-VI)</td>
<td>Moderate-High</td>
</tr>
<tr>
<td class="label">Cerebellum</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Thalamus</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Basal ganglia</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Substantia nigra</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Brainstem</td>
<td>Low-Moderate</td>
</tr>
<tr>
<td class="label">Channel</td>
<td>Subunit</td>
</tr>
<tr>
<td class="label">KCNQ2/KCNQ3</td>
<td>Kv7.2/7.3</td>
</tr>
<tr>
<td class="label">KCNQ1</td>
<td>Kv7.1</td>
</tr>
<tr>
<td class="label">Kv1.1</td>
<td>KCNA1</td>
</tr>
<tr>
<td class="label">Kv1.2</td>
<td>KCNA2</td>
</tr>
<tr>
<td class="label">Kv3.1</td>
<td>KCNC1</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>Association</td>
</tr>
<tr>
<td class="label">Alzheimer's Disease</td>
<td>Risk factor/modifier</td>
</tr>
<tr>
<td class="label">Parkinson's Disease</td>
<td>Potential modifier</td>
</tr>
<tr>
<td class="label">Epilepsy</td>
<td>Risk factor</td>
</tr>
<tr>
<td class="label">Atrial Fibrillation</td>
<td>Risk factor</td>
</tr>
<tr>
<td class="label">Long QT Syndrome</td>
<td>Modifier</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

KCNE4 (Potassium Voltage-Gated Channel Subfamily E Regulatory Subunit 4), also known as MinK-related peptide 4 (MiRP4), is a critical regulatory subunit that modulates the function of various voltage-gated potassium (Kv) channels. KCNE proteins are a family of small single-pass membrane proteins that associate with Kv channel alpha subunits to form functional channel complexes with distinct biophysical properties. KCNE4, the least characterized member of the KCNE family, is expressed in both cardiac and neuronal tissues where it plays crucial roles in regulating excitability and cellular function[@abbott2018].

In the nervous system, KCNE4-containing channels contribute to neuronal repolarization, neurotransmitter release, and synaptic plasticity. Emerging evidence suggests that KCNE4 dysfunction may contribute to neurodegenerative processes in Alzheimer's disease, Parkinson's disease, and other neurological disorders. The protein's dual expression in brain and heart also raises important considerations for therapeutic targeting, as modulators affecting KCNE4 function may have both neurological and cardiac effects[@shah2018].

Gene and Protein Structure

Gene Organization

The KCNE4 gene is located on chromosome 2q36.1 in humans, spanning approximately 6.5 kb of genomic DNA. The gene consists of 3 exons encoding a protein of 180 amino acids with a molecular weight of approximately 21 kDa. The gene is subject to alternative splicing, generating multiple transcript variants with tissue-specific expression patterns.

Protein Domain Architecture

KCNE4 shares the characteristic structure of KCNE family proteins:

N-terminal extracellular domain (1-50 aa): Short extracellular segment with potential N-linked glycosylation sites

Single transmembrane domain (51-73 aa): α-helical transmembrane segment anchoring the protein in the membrane

C-terminal cytoplasmic domain (74-180 aa): Large intracellular domain containing regulatory motifs and interaction domains

The cytoplasmic domain contains multiple phosphorylation sites and protein-protein interaction motifs that enable KCNE4 to modulate channel gating and trafficking.

Normal Physiological Function

Potassium Channel Modulation

KCNE4 associates with multiple Kv channel alpha subunits to form heteromeric channels with unique properties:

Main Channel Partners:

Kv1.x family: KCNE4 can co-assemble with Kv1.1, Kv1.2, Kv1.3, and Kv1.5 subunits to modulate their gating kinetics
Kv7.x (KCNQ) family: KCNE4 interacts with KCNQ1 (Kv7.1) and KCNQ2/3 (M-channels) to regulate neuronal excitability
Kv3.x family: Modulates high-threshold, fast-deactivating Kv channels important for fast-spiking neurons

Functional Effects:

KCNE4 binding typically produces:

Slowed activation: Delayed channel opening upon depolarization
Enhanced inactivation: Increased current decay during sustained depolarization
Shifted voltage dependence: Altered voltage sensitivity of channel activation
Modified pharmacology: Changed sensitivity to channel blockers and activators

Neuronal Function

In neurons, KCNE4-containing channels contribute to:

Membrane Repolarization: Following action potential generation, KCNE4 channels contribute to rapid repolarization, enabling high-frequency firing in fast-spiking neurons.

Resting Membrane Potential: KCNQ2/3 channels regulated by KCNE4 set the resting membrane potential and control neuronal input resistance.

Neurotransmitter Release: Presynaptic Kv channels influence calcium influx during action potentials, modulating neurotransmitter release probability.

Synaptic Integration: Dendritic Kv channels affect synaptic integration and temporal processing of incoming signals[@kawasaki2019].

Role in Neurodegenerative Diseases

Alzheimer's Disease

KCNE4 dysfunction is implicated in Alzheimer's disease (AD) through multiple mechanisms:

Amyloid-beta interaction: Aβ oligomers directly affect KCNE4 channel function. Studies show that Aβ exposure:

Reduces KCNE4 expression in hippocampal neurons
Decreases KCNQ2/3 currents, leading to hyperexcitability
Increases neuronal vulnerability to excitotoxic cell death

Channel dysfunction: Post-mortem studies of AD brains reveal altered KCNE4 expression in the hippocampus and cortex, regions critical for memory formation[@yang2019]. The changes in KCNE4 expression correlate with:

Reduced KCNQ2/3-mediated M-current
Increased neuronal excitability
Disrupted synaptic plasticity mechanisms
Enhanced susceptibility to excitotoxicity

Therapeutic implications: KCNE4 and associated KCNQ channels represent promising targets for AD therapy. Current approaches include:

KCNQ activators (retigabine, flindomer) to enhance M-current
KCNE4 expression modulators
Gene therapy approaches targeting KCNQ2/3

Parkinson's Disease

KCNE4 involvement in Parkinson's disease (PD) is an emerging area of research:

Dopaminergic neuron function: KCNE4 is expressed in dopaminergic neurons of the substantia nigra pars compacta, where it modulates Kv channel function. Changes in KCNE4 may contribute to:

Altered firing patterns in PD model systems
Increased vulnerability of dopaminergic neurons
Dysregulated dopamine release in the striatum

Neuroinflammation: KCNE4 is expressed in microglia, where Kv channels regulate microglial activation and neuroinflammatory responses[@liu2017]. Altered KCNE4 function may contribute to chronic neuroinflammation in PD.

Other Neurological Disorders

Epilepsy: KCNE4 variants have been associated with epilepsy susceptibility. KCNE4 modulates neuronal excitability, and dysfunction may contribute to seizure generation.

Stroke and excitotoxicity: Following ischemic injury, KCNE4 expression and function are altered, affecting neuronal survival and recovery[@mendelsohn2019].

Neuropathic pain: KCNE4 in sensory neurons contributes to pain signaling, and altered expression is observed in models of neuropathic pain.

Expression Patterns

Brain Region Distribution

KCNE4 exhibits region-specific and cell-type-specific expression in the central nervous system:

Cellular and Subcellular Localization

Somatic membrane: KCNE4 is localized to the soma of neurons
Dendritic membrane: Present on dendritic shafts and spines
Axon initial segment: Detected in AIS of some neuron types
Presynaptic terminals: Low levels in some synaptic terminals
Glial cells: Expressed in astrocytes and microglia

Developmental Expression

KCNE4 expression changes during development:

Low expression in embryonic brain
Gradual increase during postnatal development
Peak expression in adult brain
Age-related changes may contribute to neurodegeneration

Interacting Partners and Signaling Pathways

Channel Partners

Signaling Pathways

KCNE4 is regulated by multiple signaling mechanisms:

Phosphorylation: PKA and PKC phosphorylation modulates KCNE4 function
Trafficking: ER export and surface expression regulated by accessory proteins
Protein interactions: Interactions with scaffolding proteins like AKAP79/150
Alternative splicing: Multiple splice variants with distinct properties

Therapeutic Potential

Drug Development Targets

KCNE4 and its partner channels represent attractive therapeutic targets:

KCNQ2/3 Activators:

Retigabine (approved for epilepsy): Potentiates KCNQ2/3 currents
Flindomer (investigational): Brain-penetrant KCNQ activator
ZQ1 (preclinical): Novel opener with improved selectivity

Considerations:

KCNE4's role in both brain and heart requires careful targeting
Tissue-specific delivery approaches may be necessary
Selective targeting of specific KCNE4-containing channel complexes

Biomarker Potential

KCNE4 expression in peripheral tissues may serve as a biomarker for neuronal Kv channel function:

Lymphocyte KCNE4 expression as proxy for neuronal changes
CSF KCNE4 levels correlating with disease progression
Genetic variants as risk markers for neurodegeneration

Clinical Relevance

Disease Associations

Genetic Variants

Several KCNE4 variants have been identified:

D202N: Associated with cardiac arrhythmias
R53Q: Found in patients with epilepsy
A70T: Identified in population studies
Promoter variants: Altered expression in disease states

Summary

KCNE4 is a critical regulatory subunit of voltage-gated potassium channels with important roles in neuronal excitability, synaptic function, and cellular homeostasis. Its expression in both the brain and heart, combined with emerging evidence of dysfunction in Alzheimer's disease and Parkinson's disease, makes KCNE4 an important protein in neurodegenerative research. Understanding KCNE4's precise functions and developing targeted therapeutic approaches may provide new strategies for treating these devastating disorders.

References

[Hille B, Ionic Channels of Excitable Membranes (2001)](https://www.sinauer.com/products/ionic-channels-of-excitable-membranes-3rd-edition.html)

[Stocker M, Calcium-activated potassium channels (2004)](https://pubmed.ncbi.nlm.nih.gov/15378036/)

[Shah NH, et al., Neuronal potassium channels in neurodegeneration (2018)](https://pubmed.ncbi.nlm.nih.gov/30046008/)

[Angulo E, et al., Potassium channel dysfunction in AD (2004)](https://pubmed.ncbi.nlm.nih.gov/15140932/)

[Bean BP, Action potentials in central neurons (2007)](https://pubmed.ncbi.nlm.nih.gov/17541432/)

[Ehling P, Small-conductance calcium-activated channels (2020)](https://pubmed.ncbi.nlm.nih.gov/32877965/)

[Lüscher C, Slesinger PA, Ionotropic glutamate receptors (2010)](https://pubmed.ncbi.nlm.nih.gov/20649637/)

[Garnock-Jones KP, Group I metabotropic glutamate receptors (2017)](https://pubmed.ncbi.nlm.nih.gov/28447065/)

[Abbott GW, KCNE4 and KCNE5 in excitability (2018)](https://pubmed.ncbi.nlm.nih.gov/29566142/)

[Roepke TK, KCNE4 deletion and cardiac phenotypes (2011)](https://pubmed.ncbi.nlm.nih.gov/21888914/)

[Nerbonne JM, Kass RS, Molecular basis of cardiac ion channels (2016)](https://pubmed.ncbi.nlm.nih.gov/27137552/)

[Yang Y, et al., Potassium channels in AD (2019)](https://pubmed.ncbi.nlm.nih.gov/31176523/)

[Chen X, et al., KCNE4 and neuroprotection (2020)](https://pubmed.ncbi.nlm.nih/32750589/)

[Kawasaki H, et al., KCNE4 in rodent brain (2019)](https://pubmed.ncbi.nlm.nih.gov/31729023/)

[Wang K, et al., KCNE4 variants and cardiac disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29338912/)

[Liu Y, et al., Potassium channels in microglia (2017)](https://pubmed.ncbi.nlm.nih.gov/28029754/)

[Song W, et al., Potassium channels in excitotoxicity (2019)](https://pubmed.ncbi.nlm.nih.gov/30664538/)

[Mendelsohn AD, Potassium channels in stroke (2019)](https://pubmed.ncbi.nlm.nih.gov/31054967/)

[Cruz JD, et al., KCNE expression in brain (2018)](https://pubmed.ncbi.nlm.nih.gov/28943276/)

[Yang J, et al., KCNE4 and Aβ in neurons (2021)](https://pubmed.ncbi.nlm.nih.gov/34092706/)

[Zhang L, et al., Potassium channelopathies (2022)](https://pubmed.ncbi.nlm.nih.gov/35110568/)

📖 View canonical wiki page →

KCNE4 (Potassium Voltage-Gated Channel Subfamily E Regulatory Subunit 4)

KCNE4 (Potassium Voltage-Gated Channel Subfamily E Regulatory Subunit 4)

Overview

KCNE4 (Potassium Voltage-Gated Channel Subfamily E Regulatory Subunit 4)

Overview

Gene and Protein Structure

Gene Organization

Protein Domain Architecture

Normal Physiological Function

Potassium Channel Modulation

Neuronal Function

Role in Neurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Other Neurological Disorders

Expression Patterns

Brain Region Distribution

Cellular and Subcellular Localization

Developmental Expression

Interacting Partners and Signaling Pathways

Channel Partners

Signaling Pathways

Therapeutic Potential

Drug Development Targets

Biomarker Potential

Clinical Relevance

Disease Associations

Genetic Variants

Summary

See Also

References